Drug intelligence / Profile preview

DiaResQ

Development stage: Unknown
Lead developer: PanTheryx
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Oral

Overview

DiaResQ is a food for special dietary use (FSDU) developed by PanTheryx for the management of diarrhea in adults and children aged one year and older. It is composed of bovine colostrum and egg solids, which provide a concentrated source of immunoglobulins, bioactive proteins, and essential nutrients. Unlike pharmacological anti-motility agents or antibiotics, DiaResQ works by delivering naturally occurring immune factors directly to the intestine to support the body's natural immune response and restore normal intestinal function. It is particularly indicated for acute diarrhea and travelers' diarrhea and is administered as a powder mixed with water at the first sign of symptoms.

Brand names: DiaResQ
Other names: bovine immunoglobulinsbovine colostrum and egg solids

Beyond the preview

Go deeper on DiaResQ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiaResQ.

Explore the full profile